Sort by: after hours % change | delayed % change | gain open | gain high | gain close | publishing date
treatment publishing date : 2021 - 01 - 04 save search
Ampio Provides Update on Clinical Trials for Ampion™ Treatment of COVID-19 Patients
Published: 2021-01-04 (Crawled : 17:00) - biospace.com/
AMPE | $0.242 0.0% 15K
|
Health Technology
|
| O: 0.63%
H: 2.5%
C: -7.5%
covid trial treatment covid-19
HAWKINS ANNOUNCES IT HAS EXTENDED ITS WATER TREATMENT FOOTPRINT WITH ACQUISITIONS IN LOUISIANA
Published: 2021-01-04 (Crawled : 15:00) - globenewswire.com
HWKN 4 | $74.59 -0.15% -0.15% 360K
|
Distribution Services
|
| O: 1.13%
H: 0.49%
C: -1.89%
acquisition acquisitions treatment
European Medicines Agency Validates Bristol Myers Squibb’s Application for Opdivo (nivolumab) as Adjuvant Treatment for Resected Esophageal or Gastroesophageal Junction Cancer Following Chemoradiotherapy
Published: 2021-01-04 (Crawled : 15:00) - biospace.com/
BMY | $48.93 1.3% 0.0% 10M
|
Health Technology
|
| O: -0.47%
H: 0.66%
C: -0.58%
cancer therapy treatment application nivolumab
European Medicines Agency Validates Bristol Myers Squibb’s Application for Opdivo (nivolumab) Combined with Chemotherapy as First-Line Treatment in Metastatic Gastric Cancer, Gastroesophageal Junction Cancer and Esophageal Adenocarcinoma
Published: 2021-01-04 (Crawled : 15:00) - biospace.com/
BMY | $48.93 1.3% 0.0% 10M
|
Health Technology
|
| O: -0.47%
H: 0.66%
C: -0.58%
cancer therapy treatment application nivolumab
Harpoon Therapeutics Doses First Patient with HPN328, an Anti-DLL3 T Cell Engager for Treatment of Small Cell Lung Cancer and other DLL3-Associated TumorsHPN328, Harpoon’s fourth TriTAC® T cell engager, enters clinical development
Published: 2021-01-04 (Crawled : 15:00) - biospace.com/
HARP | $23.01 0.07% 6.6M
|
Health Technology
|
| O: 3.13%
H: 17.16%
C: 13.54%
lung cancer cancer t-cell
Ayala Pharmaceuticals to Accelerate Development of AL102 for the Treatment of Desmoid Tumors in Pivotal Phase 2/3 Study
Published: 2021-01-04 (Crawled : 13:03) - globenewswire.com
AYLA | $0.5036 5.84% -0.7% 0
|
Health Technology
|
| O: 7.21%
H: 1.76%
C: -4.52%
treatment phase 2 phase 2/3
Harpoon Therapeutics Doses First Patient with HPN328, an Anti-DLL3 T Cell Engager for Treatment of Small Cell Lung Cancer and other DLL3-Associated Tumors
Published: 2021-01-04 (Crawled : 13:00) - globenewswire.com
HARP | $23.01 0.07% 6.6M
|
Health Technology
|
| O: 3.13%
H: 17.16%
C: 13.54%
lung cancer cancer t-cell treatment
Passage Bio Receives FDA Clearance of IND Application for Lead Gene Therapy Candidate PBGM01 for Treatment of Infantile GM1 Gangliosidosis
Published: 2021-01-04 (Crawled : 12:03) - globenewswire.com
PASG | $1.15 -4.17% -4.35% 280K
|
Health Technology
|
| O: 2.35%
H: 11.2%
C: 7.45%
gene therapy fda clearance fda therapy treatment gene therapies application clearance
Inozyme Pharma Announces Authorization to Proceed in U.S. and U.K. with Phase 1/2 Clinical Trial of INZ-701 for the Treatment of ENPP1 Deficiency
Published: 2021-01-04 (Crawled : 11:03) - globenewswire.com
INZY | $4.5 -1.75% -1.78% 590K
|
Health Technology
|
| O: 4.26%
H: 11.85%
C: 8.6%
trial phase 3 phase 1 phase 2 treatment authorized
Tiziana Life Sciences plc announces completion of the clinical trial with nasally administered Foralumab, its proprietary fully human anti-CD3 monoclonal antibody, for the treatment of COVID-19 patients in Brazil
Published: 2021-01-04 (Crawled : 10:00) - biospace.com/
TLSA | News | $0.6698 4.66% 4.45% 600K
|
Health Technology
|
| O: 18.81%
H: 9.58%
C: 7.5%
covid life science brazil trial antibody foralumab
Tiziana Life Sciences plc ("Tiziana" or the "Company") - Tiziana announces completion of the clinical trial with nasally administered Foralumab, its proprietary fully human anti-CD3 monoclonal antibody, for the treatment of COVID-19 patients in Brazil
Published: 2021-01-04 (Crawled : 07:01) - globenewswire.com
TLSA | News | $0.6698 4.66% 4.45% 600K
|
Health Technology
|
| O: 18.81%
H: 9.58%
C: 7.5%
covid life science brazil trial antibody foralumab
Gainers vs Losers
| 67% | 33% |
Top 10 Gainers
GBR | $1.42 31.48% 11.27% 990K
|
Energy Minerals
KUKE | $2.88 2.49% 7.64% 360K
|
MPLN | $0.6502 -11.74% 4.51% 2.2M
|
Finance
CXM 4 | $11.34 -0.44% 4.27% 1.7M
|
Information
PVL 4 | $1.47 -0.68% 4.08% 77K
|
Energy Minerals
RNR 4 | $224.74 0.85% 3.52% 310K
|
Finance
PZG | $0.4431 0.48% 2.91% 150K
|
Non-Energy Minerals
LEV | $0.972 0.73% 2.88% 570K
|
Manufacturing
AJX 4 | $3.47 2.06% 2.02% 110K
|
Finance
LPTV 4 | $0.2941 4.55% 2.01% 340K
|
Administrative and Support and ...
Your saved searches
Save your searches and get alerts when important news are released.